Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website

Lumos Pharma Inc.

Lumos Pharma Inc. reported $63.25M in Current Assets for its fiscal quarter ending in March of 2023.

Current Assets Change
Aceragen Inc IDRA:US USD 17.86M 12.21M
Agenus AGEN:US USD 205.69M 7.43M
Capricor Therapeutics CAPR:US USD 46.6M 3.71M
Celldex Therapeutics CLDX:US USD 289.6M 28.1M
Eli Lilly LLY:US USD 20.81B 2.78B
Incyte Corp INCY:US USD 3.97B 121.22M
Intrexon XON:US USD 137.74M 19.58M
Lumos Pharma Inc. NLNK:US USD 63.25M 8.76M
Nektar Therapeutics NKTR:US USD 491.07M 54.9M
Prothena PRTA:US USD 700.34M 18.76M
Sarepta Therapeutics SRPT:US USD 2.49B 69.48M
Vascular Biogenics VBLT:US USD 26.97M 4.82M